CBD Now Approved in Multiple Countries for Drug-Resistant Childhood Epilepsy
CBD has received regulatory approval in the US, Europe, and India for three forms of drug-resistant childhood epilepsy, with evidence showing reduced seizure frequency and generally favorable safety.
Quick Facts
What This Study Found
CBD has been approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in multiple countries. Clinical trials and observational studies show it can lower seizure frequency and improve quality of life. Common adverse events include somnolence, diarrhea, and gastrointestinal issues. Cost remains a barrier, especially in low- and middle-income countries.
Key Numbers
Approved for 3 conditions: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex. Regulatory approval in US, Europe, and India. Common adverse events: somnolence, diarrhea, GI issues. Cost is a significant barrier in LMICs.
How They Did This
Narrative review of CBD's pharmacological properties, mechanisms of action, and clinical evidence from trials and observational studies for pediatric drug-resistant epilepsy, including regulatory landscape discussion.
Why This Research Matters
Drug-resistant epilepsy affects children who do not respond to conventional anti-seizure medications. CBD represents one of the few new treatment options to receive regulatory approval across multiple jurisdictions for these severe conditions.
The Bigger Picture
CBD's journey from cannabis compound to approved pharmaceutical represents a rare success in cannabinoid medicine. However, access barriers due to cost and regulatory complexity mean many children who could benefit still cannot access treatment.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Does not quantify seizure reduction across all studies. Limited discussion of long-term outcomes. Cost-effectiveness analysis not included.
Questions This Raises
- ?Can lower-cost CBD formulations achieve similar efficacy?
- ?What are the long-term developmental outcomes for children on CBD treatment?
Trust & Context
- Key Stat:
- Evidence Grade:
- Multiple regulatory approvals based on clinical trial data across three conditions places this at strong evidence, despite the review's narrative format.
- Study Age:
- Reviews current evidence and regulatory status.
- Original Title:
- Update on Cannabidiol in Drug-Resistant Epilepsy.
- Published In:
- Indian journal of pediatrics, 92(1), 61-69 (2025)
- Authors:
- Singh, Akanksha, Madaan, Priyanka, Bansal, Dipika
- Database ID:
- RTHC-07668
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which types of epilepsy can CBD treat?
CBD is approved for three drug-resistant epilepsy conditions: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Is CBD safe for children with epilepsy?
Clinical trials show a generally favorable safety profile with common side effects including sleepiness, diarrhea, and stomach issues. However, ongoing monitoring is needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07668APA
Singh, Akanksha; Madaan, Priyanka; Bansal, Dipika. (2025). Update on Cannabidiol in Drug-Resistant Epilepsy.. Indian journal of pediatrics, 92(1), 61-69. https://doi.org/10.1007/s12098-024-05337-1
MLA
Singh, Akanksha, et al. "Update on Cannabidiol in Drug-Resistant Epilepsy.." Indian journal of pediatrics, 2025. https://doi.org/10.1007/s12098-024-05337-1
RethinkTHC
RethinkTHC Research Database. "Update on Cannabidiol in Drug-Resistant Epilepsy." RTHC-07668. Retrieved from https://rethinkthc.com/research/singh-2025-update-on-cannabidiol-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.